OccuLogix, Inc.
TSX : OC
NASDAQ : OCCXD

OccuLogix, Inc.

October 15, 2008 09:00 ET

OccuLogix Provides Progress Update on the Commercial Development of Its TearLab™ Osmolarity System

TORONTO, ONTARIO--(Marketwire - Oct. 15, 2008) - OccuLogix, Inc. (NASDAQ:OCCXD)(TSX:OC) provided an update today on the progress made by its wholly-owned subsidiary, OcuSense, Inc., in the commercial development of its TearLab™ Osmolarity System ("TearLab™").

TearLab™ has recently received CE mark approval, clearing the way for sales in the European Union and all countries recognizing the CE Mark. In connection with the CE mark clearance, OcuSense has achieved multi-year agreements with four distributors for exclusive distribution of TearLab™ in five European Union countries. Beginning immediately, TearLab™ will be available in:

- United Kingdom and the Republic of Ireland distributed by the Birmingham Optical Group;

- Germany distributed by Bon Optic;

- Spain distributed by Equipsa; and

- Italy distributed by SIFI Diagnostics

Additional European countries will be added during the coming months as the Company expands its distribution network.

"The introduction of TearLab™ into the eye care market addresses the unmet need for simple, point-of-care tests that can generate objective physiological data for improving the quality of clinical decision making," said Eric Donsky, OccuLogix' CEO.

"In addition, the ability to perform tear osmolarity testing in the office, using any member of the clinical staff, is a significant improvement upon current methods of assessing tear osmolarity," continued Donsky.

About Osmolarity

Studies have shown that osmolarity, the measurement of total solute concentration in patients' tears, is objective and quantitative, and a highly specific biomarker.(i) In dry eye disease, the accuracy of tear film osmolarity is considered superior to any other single test for dry eye analysis, including Lactoplate, Schirmer's test, and corneal staining.(ii)

Measuring osmolarity using current in-lab testing technologies presents a challenge because of the need for large volumes of tear fluid. Currently, osmolarity can only be tested in reference labs, which makes this type of testing difficult because of the need to either ship samples and risk evaporation, or require the patient to travel to a lab for testing.

About TearLab™

The introduction of the TearLab™ Osmolarity System marks a significant change in how tear osmolarity testing will be conducted. The TearLab™ technology uses a novel "lab-on-a-chip" approach that requires less than 50 nL (nanoliters) of tear fluid in order to measure tear osmolarity. By using such a small amount of tears, the TearLab™ Osmolarity System mitigates issues that have hindered practical, objective point-of-care osmolarity testing. The system consists of three components: the TearLab™ Osmolarity Test Card, the TearLab™ Reader and the TearLab™ Pen.

About OccuLogix, Inc.

OccuLogix (www.occulogix.com) is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases. Its wholly-owned subsidiary, OcuSense, Inc. (www.ocusense.com) is an in vitro diagnostics company developing and commercializing novel, laboratory-on-a-card technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.



-------------------------------------

(i) Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film
osmolarity: determination of a referent for dry eye diagnosis.
Invest Ophthalmol Vis Sci 47:4309-15, 2006

(ii) Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film
osmolarity: determination of a referent for dry eye diagnosis.
Invest Ophthalmol Vis Sci 47:4309-15, 2006


Contact Information